Pathophysiology of ovarian steroid secretion in polycystic ovary syndrome

Seminars in Reproductive Endocrinology

Volumn 15, Issue 2, 1997, Pages 159-168

  Barnes, Randall B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

ovarian hyperandrogenism; P450c17; Polycystic ovary syndrome

Indexed keywords

CYTOCHROME P450; FOLLITROPIN; GONADORELIN AGONIST; LUTEINIZING HORMONE; NAFARELIN; STEROID 17,20 LYASE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLLITROPIN RELEASE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; LUTEINIZING HORMONE RELEASE; NEGATIVE FEEDBACK; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEROID RELEASE;

EID: 0030915902     PISSN: 07348630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1016297     Document Type: Article

References (61)

1. Stein IF, Leventhal ML: Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29:181-191, 1935
2. Barnes R, Rosenfield RL: The polycystic ovary syndrome: Pathogenesis and treatment. Ann Int Med 110:386-399, 1989
3. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA: Pituitary-ovarian responses to Nafarelin testing in the polycystic ovary syndrome. N Engl J Med 320:559-565, 1989
4. Rosenfield RL, Barnes RB, Ehrmann DA: Studies of the nature of 17-hydroxyprogrestrone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metabol 79:1686-1692, 1994
5. Sahin Y, Kelestimur F: 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome. Clin Endrocinol 39:151-155, 1993
6. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z: Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 327:157-162, 1992
7. Ehrmann DA, Barnes RB, Rosenfield RL: Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 16:322-353, 1995
8. Rosenfield RL, Barnes RB, Cara JF, Lucky AW: Dysregulation of cytochrome P450c17α as the cause of polycystic ovarian syndrome. Fertil Steril 53:785-791, 1990
9. 55-steroid dehydrogenase deficiency. J Clin Endocrinol Metab 76:450-455, 1993
10. Ibanez L, Potau N, Virdis R, et al: Postpubertal outcome in girls diagnosed of premature pubarche during childhood: Increased frequency of functional ovarian hyderandrogenism. J Clin Endocrinol Metab 76:1599-1603, 1993
11. Apter D, Butzow T, Laughlin GA, Yen SSC: Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: Relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab 79:119-125, 1994
12. Franks S: Polycystic ovary syndrome: A changing perspective. Clin Endocrinol 31:87-120, 1989
13. Clayton RN, Ogden V, Hodgkinson J, et al: How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin Endocrinol 137:127-134, 1992
14. Franks S: Polycystic ovary syndrome. N Engl J Med 333:853-861, 1995
15. White D, Leigh A, Wilson C, Donaldson A, Franks S: Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin Endocrinol 42:475-481, 1995
16. Suikkari AM, MacLachlan V, Montalto J, et al: Ultrasonographic appearance of polycystic ovaries is associated with exaggerated ovarin androgen and oestradial responses to gonadotrophin-releasing hormone agonist in women undergoing assisted reproduction treatment. Hum Reprod 10:513-519, 1995
17. Barnes RB: Diagnosis and therapy of hyperandrogenism. Clin Obstet Gynecol (in press)
18. Homburg R, Eshel A, Kilborn J, et al: Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries. Hum Reprod 5:32-35, 1990
19. Scheele F, Hompes PGA, van Der Meer M, et al: The effects of a gonadotrophin-releasing hormone agonist on treatment with low dose follicle stimulating hormone in polycystic ovary syndrome. Hum Reprod 8:699-704, 1993
20. Gilling-Smith C, Willis DS, Beard RW, Franks S: Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 79:1158-1165, 1994
21. Futterweit W: Pathophysiology of polycystic ovarian syndrome. In Redmond GP (ed): Androgenic Disorders. New York, Raven Press, Ltd., 1995, pp 77-166
22. Barnes RB, Rosenfield RL, Ehrmann DA, et al: Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: Evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 79:1328-1333, 1994
23. Ghizzoni L, Virdis R, Vottero A, et al: Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 81:601-606, 1996
24. Barnes RB, Rosenfield RL: Masculinization of the human pituitary-ovarian axis by perinatal androgen exposure: Polycystic ovary syndrome (PCOS) in congenital adrenal virilizing disease (CAVD). Endo Soc (Abstract) 1217, 1991
25. McKenna TJ: Pathogenesis and treatment of polycystic ovary syndrome. N Engl J Med 318:558-562, 1988
26. Dunaif A, Graf M, Mandeli J, Lauma V, Dobrjansky A: Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 65:499-507, 1987
27. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174, 1989
28. Rajkhowa M, Bicknell J, Jones M, Clayton RN: Insulin sensitivity in women with polycystic ovary syndrome: Relationship to hyperandrogenemia. Fertil Steril 61:605-612, 1994
29. Rittmaser RS, Deshwal N, Lehman L: The role of adrenal hyperandrogenism, insulin resistance, and obesity in the pathogenesis of polycystic ovarian syndrome. J Clin Endocrinol Metab 76:1295-1300, 1993
30. Chang RJ, Nakamura RM, Judd HL, Kaplan SA: Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57:356-359, 1983
31. Jialal I, Naiker P, Reddi K, Moodley J, Joubert SM: Evidence for insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 64:1066-1069, 1987
32. Morales AJ, Laughlin GA, Butzow T, et al: Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: Common and distinct features. J Clin Endocrinol Metab 81:2854-2864, 1996
33. Ovesen P, Moller J, Ingerslev HJ, et al: Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab 77:1636-1640, 1993
34. Holte J, Bergh T, Berne C, et al: Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 78:1052-1058, 1994
35. Pasquali R, Antenucci D, Casimirri F, et al: Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 68:173-179, 1989
36. Kiddy DS, Hamilton-Fairley D, Bush A, et al: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 36:105-111, 1992
37. Wabitsch M, Hauner H, Heinze E, et al: Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. J Clin Endocrinol Metab 80:3469-3475, 1995
38. Holte J, Bergh T, Berne, et al: Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 80:2586-2593, 1995
39. Elkind-Hirsch KE, Valdes CT, McConnell TG, Malinak LR: Androgen responses to acutely increased endogenous insulin levels in hyperandrogenic and normal cycling women. Fertil Steril 55:486-491, 1991
40. Moghetti P, Castello R, Negri C, et al: Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: Apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 81:881-886, 1996
41. Rosenfield RL: Editorial: Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved. J Clin Endocrinol Metab 81:878-880, 1996
42. Nestler JE, Barlascini CO, Matt DW, et al: Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 68:1027-1032, 1989
43. Prelevic GM, Wurzburger MI, Balint-Peric L, Nesic JS: Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet 336:900-903, 1990
44. Dunaif A, Scott D, Finegood D, et al: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:3299-3306, 1996
45. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome P450c17 activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335:617-623, 1996
46. Zhang LH, Rodriguez H, Ohno S, Miller WL: Serine phosphorylation of human P450c17 increases 17,20-lyase activity: Implications for adrenarche and the polycystic ovary syndrome. Med Sciences 92:10619-10623, 1995
47. Dunaif A, Xia J, Book CB, et al: Excessive insulin receptor serine phophorylation in cultured fibroblasts and in skeletal muscle. J Clin Invest 96:801-810, 1995
48. Dunaif A: Insulin resistance and ovarian hyperandrogenism. Endocrinologist 2:248-260, 1992
49. Bjorntorp P: The android women - A risky condition. J Intern Med 239:105-110, 1996
50. Dunaif A, Green G, Futterweit W, Dobrjansky A: Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 70:699-704
51. Kirschner MA, Samojlik E, Drejka M, et al: Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 70:473-478, 1990
52. Lovejoy JC, Bray GA, Bourgeois MO, et al: Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women - A clinical research center study. J Clin Endocrinol Metab 81:2198-2203, 1996
53. Kissebah AH, Vydelingum N, Murray R, et al: Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54:254-260, 1982
54. Peiris AN, Struve MF, Mueller RA, et al: Glucose metabolism in obesity: Influence of body fat distribution. J Clin Endocrinol Metab 67:760-767, 1988
55. Speiser PW, Serrat J, New MI, Gertner JM: Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 75:1421-1424, 1992
56. Giudice LC, Cataldo NA, van Dessel T, et al: Growth factors in normal ovarian follicle development. Reprod Endocrinol 14:179-196, 1996
57. Giudice LC, Morales AJ, Yen SSC: Growth factors and polycystic ovarian syndrome. Reprod Endocrinol 14:203-08, 1996
58. Rabin D, Spitz I, Bergovici B, et al: Isolated deficiency of follicle-stimulating hormone. N Engl J Med 287:1313-1317, 1972
59. Matthews CH, Borgato S, Peccoz B, et al: Primary amenorrhoea and infertility due to a mutation in the β-subunit of follicle-stimulating hormone. Nature Genet 5:83-86, 1993
60. Smyth CD, Miro F, Whitelaw PF, et al: Ovarian thecal/interstitial androgen synthesis is enhanced by a follicle-stimulating hormone-stimulated paracrine mechanism. Endocrinology 133:1532-1538, 1993
61. Levrant SG, Barnes RB, Rosenfield RL: A comparison of hCG to nafarelin stimulation in functional ovarian hyperandrogenism. Presented at the 42nd Annual Meeting, Society for Gynecologic Investigation, Chicago, IL, March 16-18, 1995